What is Jupiter Neurosciences, Inc. (JUNS)?

Jupiter Neurosciences, Inc. (JUNS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of JUNS?

The current price of JUNS is $2.50. Prices are updated in real time on Stocks360.

What is JUNS's price-to-earnings (PE) ratio?

JUNS's trailing twelve-month PE ratio is -0.13, based on current price and earnings per share data available on Stocks360.

What is JUNS's market capitalization?

JUNS's market capitalization is $3,296,303.00, placing it in the small-cap tier.

Jupiter Neurosciences, Inc. (JUNS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$2.50

Market Cap

$3.30M

PE (TTM)

-0.13

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.88

Day Range

$2.40 – $2.70

52-wk Range

$2.25 – $127.50

Avg Volume

N/A

Volume

29.72K

Jupiter Neurosciences, Inc. (JUNS) is a publicly traded company in the Healthcare sector. Latest price: $2.50. Market cap $3.30M. Trailing PE -0.13. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $107.25 2026-10-28 · $2.50 (-97.67%)

Earnings

Most Recent

Aug 14, 2026

EPS $-5.06 vs est. $-3.75

Missed by $1.31

Next Earnings

Dec 2, 2026

EPS estimate $-3.75

Proprietary Signals

Signal snapshot temporarily unavailable.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.13×
P/S (TTM)	50.95×
P/B	-3.81×
PEG	0.00×
P/FCF (TTM)	-0.45×
EV / EBITDA	-0.38×
EV / Sales	54.47×
Earnings Yield	-659.97%
Free Cash Flow Yield	-219.93%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$3.52M
Revenue (TTM)	$64.69K
Net Income (TTM)	-$21.75M
Free Cash Flow (TTM)	-$7.04M
Net Debt	$227.20K
Working Capital	-$1.33M
Gross Margin	88.34%
Operating Margin	-15166.68%
Net Margin	-14220.12%
Return on Equity	747.33%
Return on Invested Capital	-709.40%